BevacizumabIn First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma

被引：0
|
作者：
James E. Frampton
Gillian M. Keating
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
BioDrugs | 2008年 / 22卷
关键词：
Vascular Endothelial Growth Factor; Renal Cell Carcinoma; Bevacizumab; Sorafenib; Erlotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
▴ Bevacizumab, an anti-vascular endothelial growth factor recombinant humanized monoclonal antibody, directly inhibits tumor angiogenesis and hence tumor growth.
引用
收藏
页码：113 / 120
页数：7
相关论文
共 50 条
  • [41] Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
    Yaman, Samet
    Bilgin, Burak
    Sendur, Mehmet A. N.
    Hizal, Mutlu
    Akinci, Muhammed Bulent
    Yalcin, Bulent
    FUTURE ONCOLOGY, 2019, 15 (09) : 925 - 927
  • [42] The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma
    Calvo, Emiliano
    Porta, Camillio
    Grunwald, Viktor
    Escudier, Bernard
    ONCOLOGIST, 2019, 24 (03) : 338 - 348
  • [43] Optimizing treatment for metastatic renal cell carcinoma
    Patard, Jean-Jacques
    Porta, Camillo
    Wagstaff, John
    Gschwend, Juergen E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (12) : 1901 - 1911
  • [44] Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab
    Singh, Abhay
    Singh, Inderpreet
    Singh, Namrata
    Puzanov, Igor
    ONCOTARGETS AND THERAPY, 2020, 13 : 4021 - 4034
  • [45] Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma
    Wang, Siying
    Xie, Ouyang
    Wu, Meiyu
    Xiang, Heng
    Tan, Chongqing
    Wan, Xiaomin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (02) : 173 - 178
  • [46] Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
    Bianconi, Maristella
    Faloppi, Luca
    Loretelli, Cristian
    Zizzi, Antonio
    Giampieri, Riccardo
    Bittoni, Alessandro
    Andrikou, Kalliopi
    Del Prete, Michela
    Burattini, Luciano
    Montironi, Rodolfo
    Scartozzi, Mario
    Cascinu, Stefano
    ONCOTARGET, 2016, 7 (25) : 37599 - 37607
  • [47] Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting
    de Velasco, Guillermo
    Hamieh, Lana
    Mickey, Suzanne
    Choueiri, Toni K.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (12) : 538 - 545
  • [48] Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
    Koie, Takuya
    Ohyama, Chikara
    Yoneyama, Takahiro
    Yamamoto, Hayato
    Imai, Atsushi
    Hatakeyama, Shingo
    Hashimoto, Yasuhiro
    Yoneyama, Tohru
    Tobisawa, Yuki
    Mori, Kazuyuki
    BMC UROLOGY, 2015, 15
  • [49] Managing First-Line Metastatic Renal Cell Carcinoma Favorable-Risk Disease
    Pan, Elizabeth
    Urman, Danielle
    Malvar, Carmel
    McKay, Rana R.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (05) : 943 - 949
  • [50] Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore
    Pruis, Sil-ling
    Aziz, Mohamed Ismail Abdul
    Pearce, Fiona
    Tan, Min Han
    Wu, David Bin-Chia
    Ng, Kwong
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2019, 35 (02) : 126 - 133
12345